<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603083</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2007-003890-20</org_study_id>
    <secondary_id>S-20070066</secondary_id>
    <nct_id>NCT00603083</nct_id>
  </id_info>
  <brief_title>Postoperative Pain Treatment in Total Hip Arthroplasty: A Study to Assess the Effect of Local Analgesia</brief_title>
  <official_title>Postoperative Pain Treatment in Total Hip Arthroplasty A Randomized Double-blinded Placebo-controlled Study to Assess the Effect of Local Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the investigator standardized pain&#xD;
      treatment plus local pain treatment is more effective than the investigator standardized pain&#xD;
      treatment plus placebo in total hip arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and Vomiting (PONV)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>2 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine, Ketorolac and Adrenalin</intervention_name>
    <description>The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Naropin</other_name>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for an uncemented unilateral Total Hip Replacement because of osteoarthritis&#xD;
&#xD;
          -  Willingness and possibility to follow the instructions of the study&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  written informed consent and authority after it has been read and understood.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Operation with anterior approach or using navigation&#xD;
&#xD;
          -  Do not understand or speech danish&#xD;
&#xD;
          -  Can not use the pain-score Numerical Rating Scale (NRS)&#xD;
&#xD;
          -  Special indications for Total Hip Replacement&#xD;
&#xD;
          -  Anaesthetized in general anaesthesia where a tube is demanded&#xD;
&#xD;
          -  Daily use of strong opioids, based on the investigators assessment&#xD;
&#xD;
          -  Fertile women&#xD;
&#xD;
          -  ASA-score: 3 and 4&#xD;
&#xD;
          -  Known allergy against the standardized pain treatment, the study drugs and placebo,&#xD;
             Ropivacaine, Ketorolac, Adrenalin.&#xD;
&#xD;
          -  Treatment with Lithium, Dihydroergotamin, full anticoagulant treatment or&#xD;
             MAO-inhibitor&#xD;
&#xD;
          -  Following illness:&#xD;
&#xD;
          -  Active gastric ulcer or earlier gastrointestinal bleeding, ulceration or perforation&#xD;
             of any kind.&#xD;
&#xD;
          -  Suspicions of manifest gastrointestinal bleeding and/or cerebrovascular bleeding&#xD;
&#xD;
          -  Haemorrhagic diathesis&#xD;
&#xD;
          -  Coagulation disorder&#xD;
&#xD;
          -  Severe thrombocytopenia&#xD;
&#xD;
          -  Severe heart insufficiency&#xD;
&#xD;
          -  Severe risk of postoperative bleeding or delayed haemostatic&#xD;
&#xD;
          -  Myocardium hypertrophy or ischaemic heart disease&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Hypovolemics&#xD;
&#xD;
          -  Anhydration&#xD;
&#xD;
          -  angiooedema&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Bronchospasm&#xD;
&#xD;
          -  Severe liver insufficiency&#xD;
&#xD;
          -  Rhinostenosis because of polyostotic&#xD;
&#xD;
          -  Narrow-angled glaucoma&#xD;
&#xD;
          -  Phaeochromocytoma&#xD;
&#xD;
          -  Low plasm-potassium&#xD;
&#xD;
          -  Thyreotoxicosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Kjaersgaard-Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ortopaedic Department, Vejle Hospital, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orthopaedic Department</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortopaedic Department, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>January 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>December 8, 2011</last_update_submitted>
  <last_update_submitted_qc>December 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vejle Hospital</investigator_affiliation>
    <investigator_full_name>Per Kjaersgaard-Andersen</investigator_full_name>
    <investigator_title>Per Kjaersgaard-Andersen MD</investigator_title>
  </responsible_party>
  <keyword>Hip Arthroplasty</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Local Anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

